Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 20/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19451509 | 1.00 | STING1 (0.84) | STING1CYP3A4TBK1 | |
| SCHEMBL29586400 | 1.00 | STING1 (0.84) | STING1CYP3A4TBK1 | |
| SCHEMBL29626044 | 1.00 | STING1 (0.84) | STING1CYP3A4TBK1 | |
| SCHEMBL25074339 | 0.97 | STING1 (0.80) | STING1CYP3A4TBK1 | |
| SCHEMBL20066383 | 0.96 | STING1 (0.81) | STING1CYP3A4TBK1 | |
| SCHEMBL23227988 | 0.96 | STING1 (0.78) | STING1CYP3A4TBK1 | |
| SCHEMBL19451711 | 0.96 | STING1 (0.78) | STING1CYP3A4TBK1 | |
| SCHEMBL19451513 | 0.96 | STING1 (0.80) | STING1CYP3A4TBK1 | |
| SCHEMBL20066425 | 0.95 | STING1 (0.75) | STING1CYP3A4TBK1 | |
| SCHEMBL20066435 | 0.94 | STING1 (0.75) | STING1CYP3A4TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111194214-A | Methods of administering STING agonists | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-05-22 | — | — | CN | claimed |
| CN-118215475-A | Adjuvant compositions comprising STING agonists | 葛兰素史克生物有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20230071675-A1 | Heterocyclic Amides Useful as Protein Modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-03-09 | — | — | US | disclosed |
| CN-113549110-A | Heterocyclic amides as protein modulators | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-10-26 | — | — | CN | disclosed |
| CN-109608443-B | Heterocyclic amides as protein modulators | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-109071514-B | Heterocyclic amides as protein modulators | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-07-06 | — | — | CN | disclosed |
| CN-111194214-A | Methods of administering STING agonists | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-05-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230071675-A1 | Heterocyclic Amides Useful as Protein Modulators | RB1, RBBP5, RCC2 | STING1 3127/4885CYP3A4 4195/4885TBK1 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.